222. 一次性ネフローゼ症候群 ［臨床試験数：152，薬物数：167（DrugBank：61），標的遺伝子数：50，標的パスウェイ数：174］
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03970577 | December 1, 2019 | 4 November 2019 | RItuximab From the FIRst Episode of Idiopathic Nephrotic Syndrome | Rituximab From the First Episode of Minimal Change Nephrotic Syndrome for Preventing Relapse Risk in Adult Patients: a Multicenter Randomized Controlled Trial | Minimal Change Nephrotic Syndrome (MCNS) | Drug: Rituximab;Drug: Prednisone | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | All | 148 | Phase 2 | ||
| 2 | NCT04154787 | November 29, 2019 | 11 November 2019 | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | A Randomized, Treatment Open-label, Dose-blinded Parallel Group, Three Arm, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: LNP023;Drug: Rituximab | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 72 | Phase 2 | ||
| 3 | NCT02399462 | November 2019 | 7 October 2019 | Acthar for Treatment of Post-transplant FSGS | Acthar for Treatment of Post-transplant FSGS | FSGS;Renal Transplantation;Kidney Transplantation | Drug: Acthar | University of North Carolina, Chapel Hill | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States |
| 4 | NCT03949855 | November 2019 | 14 October 2019 | Belimumab With Rituximab for Primary Membranous Nephropathy | Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI) | Membranous Nephropathy;MN | Drug: Rituximab;Drug: Placebo for Belimumab;Drug: Belimumab | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);GlaxoSmithKline | Not recruiting | 18 Years | 75 Years | All | 124 | Phase 2 | United States;Canada |
| 5 | NCT04145440 | October 15, 2019 | 4 November 2019 | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) | Glomerulonephritis, Membranous;antiPLA2R Positive | Drug: MOR202 | MorphoSys AG | Metronomia;Q2 Solutions;IQVIA Ltd | Recruiting | 18 Years | 80 Years | All | 30 | Phase 1/Phase 2 | France |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04009668 | October 2, 2019 | 14 October 2019 | Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | Precision Medicine Proof of Concept for Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease | FSGS;MCD;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: adalimumab | University of Michigan | New York University | Recruiting | 6 Years | 70 Years | All | 8 | Phase 2 | United States |
| 7 | JPRN-UMIN000038242 | 2019/10/01 | 5 November 2019 | The effect of Evolocumab on primary nephrotic syndrome | The effect of Evolocumab on primary nephrotic syndrome - The effect of Evolocumab on primary nephrotic syndrome | Primary nephrotic syndrome | Evolocumab | Department of Nephrology, Nippon Medical School | Recruiting | 16years-old | Not applicable | Male and Female | 10 | Not selected | Japan | |
| 8 | NCT03804359 | September 2019 | 26 August 2019 | Personalized Medicine for Membranous Nephropathy | Personalized Medicine for Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Rituximab | Centre Hospitalier Universitaire de Nice | Not recruiting | 18 Years | N/A | All | 64 | Phase 2 | France | |
| 9 | NCT03763643 | July 1, 2019 | 11 November 2019 | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant | Focal Segmental Glomerulosclerosis | Drug: Rituximab;Drug: Placebo;Procedure: Plasmapheresis | University of Minnesota | United States Department of Defense | Recruiting | 1 Year | 40 Years | All | 160 | Phase 1/Phase 2 | United States |
| 10 | ChiCTR1900022943 | 2019-05-03 | 5 May 2019 | Population Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic Syndrome | Population Pharmacokinetic Study for Tacrolimus in Pediatric Patients with Primary Nephrotic Syndrome | Nephrotic Syndrome | Case Series:Tacrolimus; | Children's Hospital, Zhejiang University School of Medicine | Recruiting | Both | Case Series:100; | Phase 4 | China | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2018-003437-15-FR | 03/04/2019 | 30 April 2019 | Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome | Rituximab from the FIRst Episode of Idiopathic Nephrotic Syndrome - RIFIREINS | Minimal Change Nephrotic Syndrome (MCNS) MedDRA version: 20.0 Level: LLT Classification code 10029168 Term: Nephrotic syndrome with lesion of minimal change glomerulonephritis System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: MabThera Product Name: MabThera Pharmaceutical Form: Solution for infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISONE Other descriptive name: PREDNISONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 20- | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS | Authorised | Female: yes Male: yes | 148 | Phase 2 | France | |||
| 12 | ChiCTR1900021757 | 2019-03-01 | 11 March 2019 | A randomized controlled trial for hydroxychloroquine sulfate in the treatment of idiopathic membranous nephropathy | The efficacy and safety of hydroxychloroquine sulfate in idiopathic membranous nephropathy: A randomized, controlled, Single-center clinical trial | Idiopathic Membranous Nephropathy | Group 1:Supportive treatment+Perindopril 8 mg/day;Group 2:Supportive treatment+Perindopril 8 mg/day+hydroxychloroquine sulfate (200mg 2/d);Group 3:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml);Group 4:Low dose glucocorticoid (0.5mg/kg.d)+cyclosporine A (valley concentration controlled at 50-100ng/ml)+hydroxychloroquine sulfate (200mg 2/d); | Nephrology Division, First Hospital Affiliated to Army Medical University | Recruiting | 18 | 60 | Both | Group 1:55;Group 2:55;Group 3:55;Group 4:55; | Phase 4 | China | |
| 13 | ChiCTR1800019833 | 2019-01-01 | 4 December 2018 | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone | Dynamic changes of TCM syndrome types of idiopathic membranous nephropathy treated with cyclophosphamide combined with hormone | Idiopathic Membranous Nephropathy | PLA2R???:Cyclophosphamide combined with hormone therapy ;PLA2R positive Group:Cyclophosphamide combined with hormone therapy; | Department of Nephrology, The First Affiliated Hospital of Zhejiang Chinese Medical University | Not Recruiting | 18 | 85 | Male | PLA2R???:30;PLA2R positive Group:30; | Pilot study | China | |
| 14 | ChiCTR1800020241 | 2019-01-01 | 14 January 2019 | Investigation for Risk Factors of Membrane Nephropathy in Guangxi and Study for Intervention of Vitamin D | Disease diagnosis and treatment technology and standardized research and development and application demonstration | Idiopathic membranous nephropathy | Vitamin D group:Active Vitamin D 0.5ug/day;Valsartan group:Valsartan capsule 160mg/day;Combined treatment group:Active vitamin D 0.5ug / day + valsartan capsule 160mg / day; | The People's Hospital of Guangxi Zhuang Autonomous Region | Recruiting | 14 | 100 | Both | Vitamin D group:40;Valsartan group:40;Combined treatment group:40; | Other | China | |
| 15 | NCT03864250 | November 26, 2018 | 15 July 2019 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy: A Randomized, Open, Controlled, Multicenter Clinical Trial | Tacrolimus;Idiopathic Membranous Nephropathy;Clinical Trial | Drug: Tacrolimus;Drug: Prednisone | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | 18 Years | 80 Years | All | 124 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2016-005141-23-PL | 20/11/2018 | 4 December 2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 Product Name: over-encapsulated 75 mg Irbesartan Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 300 | Phase 3 | United States;Taiwan;Spain;Italy;United Kingdom;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;South Africa;Germany;Korea, Republic of | |||
| 17 | NCT03448692 | October 15, 2018 | 9 September 2019 | A Study To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis | A PHASE 2, 12-WEEK, ADAPTIVE, OPEN LABEL, SEQUENTIAL COHORT TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06730512 FOLLOWING MULTIPLE DOSES IN ADULT SUBJECTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) | Drug: PF-06730512 | Pfizer | Recruiting | 18 Years | N/A | All | 44 | Phase 2 | United States;Canada | |
| 18 | NCT03703908 | October 1, 2018 | 24 June 2019 | A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome | An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome | Focal Segmental Glomerulosclerosis | Drug: CCX140-B | ChemoCentryx | Recruiting | 18 Years | N/A | All | 13 | Phase 2 | United States | |
| 19 | EUCTR2016-005141-23-ES | 28/09/2018 | 10 October 2018 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03 Product Name: over-encapsulated 75 mg Irbesartan Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 300 | Phase 3 | United States;Taiwan;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;South Africa;Germany;Korea, Republic of | |||
| 20 | NCT03649152 | September 17, 2018 | 10 December 2018 | Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan | A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Safety and Efficacy of Propagermanium in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving Irbesartan | Focal Segmental Glomerulosclerosis | Drug: Propagermanium;Drug: Placebo | Dimerix Bioscience Pty Ltd | IQVIA | Recruiting | 18 Years | 80 Years | All | 10 | Phase 2 | Australia |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | EUCTR2016-005141-23-CZ | 05/09/2018 | 7 January 2019 | Effectiveness and Safety of Sparsentan as treatment for Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) | Focal segmental glomerulosclerosis (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Trade Name: Irbesartan tablets Product Name: over-encapsulated Irbesartan Tablets Pharmaceutical Form: Capsule, hard INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 75- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 300 | Phase 3 | United States;Taiwan;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Canada;Poland;Australia;Denmark;Germany;Korea, Republic of | |||
| 22 | NCT03298698 | August 22, 2018 | 3 September 2018 | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome | Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone | Idiopathic Nephrotic Syndrome;Minimal Change Disease;Focal Segmental Glomerulosclerosis | Drug: Rituximab;Drug: Prednisone | Radboud University | Recruiting | 18 Years | N/A | All | 40 | Phase 3 | Netherlands | |
| 23 | NCT03549663 | July 4, 2018 | 15 April 2019 | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) | Random, Open, Control and Monocentric Clinical Research on Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: Tacrolimus;Drug: Prednisone | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | 18 Years | 80 Years | All | 108 | N/A | China | |
| 24 | ChiCTR1800016140 | 2018-07-01 | 21 May 2018 | Comparison of the efficacy and safety of tacrolimus and glucocorticoid combined with cyclophosphamide in the treatment of adult primary membranous nephropathy: a multicenter, controlled, open study | A randomized controlled trial for the treatment of primary membranous nephropathy | primary membranous nephropathy | Tacrolimus group:Tacrolimus 0.05-0.1mg/kg/d;Cyclophosphamide group:CTX 750mg/m2 ivgtt q2w for 8 weeks, then q4w for 4 weeks; | Sichuan Provincial People's Hospital | Not Recruiting | 18 | 65 | Both | Tacrolimus group:45;Cyclophosphamide group:45; | Post-market | China | |
| 25 | NCT03170323 | July 1, 2018 | 1 April 2019 | Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy | A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Cyclosporins;Drug: Mycophenolate Mofetil | Guangdong General Hospital | Recruiting | 18 Years | N/A | All | 128 | Phase 4 | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT03598036 | June 21, 2018 | 26 August 2019 | Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis | An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Voclosporin | Aurinia Pharmaceuticals Inc. | Recruiting | 18 Years | 75 Years | All | 20 | Phase 2 | United States;Dominican Republic | |
| 27 | NCT03459443 | June 20, 2018 | 30 September 2019 | A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471 | C3 Glomerulonephritis;C3 Glomerulopathy;Immune Complex Membranoproliferative Glomerulonephritis;IC-MPGN;Dense Deposit Disease | Drug: ACH-0144471 | Achillion Pharmaceuticals | Not recruiting | 17 Years | 65 Years | All | 22 | Phase 2 | United States;Australia;Belgium;Italy;Netherlands | |
| 28 | EUCTR2017-003021-15-PL | 19/06/2018 | 15 October 2018 | A controlled study to evaluate the safety and efficacy of the study drug, CCX140-B, in subjects with Focal Segmental Glomerulosclerosis (a type of glomerular disease) | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Code: CCX140-B Pharmaceutical Form: Tablet INN or Proposed INN: INN not available yet Current Sponsor code: CCX140-B Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use | ChemoCentryx, Inc. | Authorised | Female: yes Male: yes | 40 | Phase 2 | France;United States;Czech Republic;Canada;Poland;Australia;Germany;New Zealand;Italy;United Kingdom | |||
| 29 | NCT03536754 | May 1, 2018 | 2 September 2019 | A Study of CCX140-B in Subjects With FSGS | A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS) | FSGS;Focal Segmental Glomerulosclerosis;Glomerulosclerosis | Other: Placebo;Drug: CCX140-B | ChemoCentryx | Medpace, Inc. | Not recruiting | 18 Years | 75 Years | All | 46 | Phase 2 | United States;Australia;Canada;France;Italy;New Zealand;Poland;United Kingdom |
| 30 | NCT03422510 | April 15, 2018 | 26 August 2019 | FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) | Primary Focal Segmental Glomerulosclerosis | Drug: CXA-10 | Complexa, Inc. | Kidney Research Network, formerly NephCure Accelerating Cures Institute;Medpace, Inc.;MicroConstants;Arkana Labs;NephCure Kidney International | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT03493685 | March 29, 2018 | 26 August 2019 | Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) | A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS | Focal Segmental Glomerulosclerosis | Drug: sparsentan;Drug: irbesartan | Retrophin, Inc. | Recruiting | 8 Years | 75 Years | All | 300 | Phase 3 | United States;Australia;Canada;Czechia;Denmark;Estonia;France;Hungary;Italy;Korea, Republic of;Poland;Spain;Taiwan;United Kingdom | |
| 32 | NCT03466801 | March 20, 2018 | 11 June 2018 | The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. | The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I. | Idiopathic Membranous Nephropathy | Drug: Prednisone;Drug: MP and CTX | Wenhu Liu | Not recruiting | 18 Years | 80 Years | All | 166 | N/A | ||
| 33 | NCT03025828 | March 19, 2018 | 1 April 2019 | Adrenocorticotropic Hormone in Membranous Nephropathy | Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy | Membranous Nephropathy | Drug: ACTHar | Icahn School of Medicine at Mount Sinai | Recruiting | 18 Years | 70 Years | All | 25 | Phase 4 | United States | |
| 34 | ChiCTR1800014719 | 2018-02-01 | 5 February 2018 | A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosis | A retrospective control study of low concentration of tacrolimus combined with prednisone in the treatment of idiopathic focal segmental glomerulosclerosis | idiopathic focal segmental glomerulosclerosis | tacrolimus group:nothing;prednisone group:nothing; | the First Affiliated Hospital of Third Military Medical University | Recruiting | Both | tacrolimus group:24;prednisone group:17; | Retrospective study | China | |||
| 35 | NCT03453619 | January 22, 2018 | 28 January 2019 | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies | A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease) | IgA Nephropathy;Lupus Nephritis;Membranous Nephropathy;C3 Glomerulonephritis;Dense Deposit Disease | Drug: APL-2 | Apellis Pharmaceuticals, Inc. | Recruiting | 18 Years | N/A | All | 48 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | EUCTR2017-001821-42-BE | 15/01/2018 | 28 February 2019 | A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of a group of related conditions that cause the kidneys to malfunction, called C3 Glomerulopathy. | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy | C3 glomerulopathy (C3G) is characterized by evidence of alternative complement activation based on C3 deposition in the glomeruli. There are two forms of the disease: dense deposit disease (DDD, formerly called membranoproliferative glomerulonephritis [MPGN] Type II) and C3 glomerulonephritis (C3GN, formerly called idiopathic MPGN). MedDRA version: 20.0 Level: PT Classification code 10077827 Term: C3 glomerulopathy System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Product Name: Avacopan Product Code: CCX168 Pharmaceutical Form: Capsule INN or Proposed INN: AVACOPAN CAS Number: 1346623-17-3 Current Sponsor code: CCX168 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use | ChemoCentryx, Inc. | Authorised | Female: yes Male: yes | 88 | Phase 2 | France;United States;Canada;Spain;Belgium;Ireland;Denmark;Netherlands;Germany;Italy;United Kingdom | |||
| 37 | NCT03366337 | December 26, 2017 | 24 June 2019 | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases | IgA Nephropathy;CKD Associated With Type 1 Diabetes;Focal Segmental Glomerulosclerosis;Autosomal Dominant Polycystic Kidney | Drug: Bardoxolone methyl capsules | Reata Pharmaceuticals, Inc. | Not recruiting | 18 Years | 65 Years | All | 103 | Phase 2 | United States | |
| 38 | EUCTR2017-003366-27-NL | 21/12/2017 | 8 January 2018 | Comparison of rituximab with prolonged treatment with prednisone in patients with idiopathic nephrotic syndrome | Efficacy of rituximab in comparison to continued corticosteroid treatment in idiopathic nephrotic syndrome unresponsive to 8 weeks of high dose prednisone. - Rituximab in SRNS | Idiopathic nephrotic syndrome Focal segmental glomerulosclerosis Minimal change disease ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Rituximab Pharmaceutical Form: Concentrate for solution for injection/infusion INN or Proposed INN: RITUXIMAB CAS Number: 174722-31-7 Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number: 375- Product Name: Prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: Prednisolone Other descriptive name: PREDNISOLONE ACETATE Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: 1- | Radboud University Nijmegen Medical Center | Authorised | Female: yes Male: yes | 40 | Phase 3 | Netherlands | |||
| 39 | NCT03285711 | October 6, 2017 | 28 October 2019 | Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) | A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN) | Lupus Membranous Nephropathy | Drug: Filgotinib;Drug: Lanraplenib;Drug: Filgotinib placebo;Drug: Lanreplenib placebo | Gilead Sciences | Not recruiting | 18 Years | 75 Years | All | 9 | Phase 2 | United States | |
| 40 | ChiCTR-INR-17012070 | 2017-09-19 | 24 July 2017 | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Yongquan acupoint Shenque moxibustion curative effect of traditional Chinese medicine in the treatment of membranous nephropathy | Membranous nephropathy | Test group :Yongquan Shenque paste of Chinese medicine with mild moxibustion;control group:Valsartan Tablets; | Shijiazhuang Nephropathy Hospital | Not Recruiting | 18 | 75 | Both | Test group :75;control group:75; | New Treatment Measure Clinical Study | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT03095118 | September 7, 2017 | 28 October 2019 | Daratumumab in Treatment of PGNMID and C3 GN | Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy | Membranoproliferative Glomerulonephritis | Drug: Daratumumab | Fernando Fervenza | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States | |
| 42 | NCT03124368 | August 9, 2017 | 11 November 2019 | A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN | A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | C3 Glomerulonephritis;Dense Deposit Disease;Membranoproliferative Glomerulonephritis, Type II;C3 Glomerulopathy;Immune Complex Mediated Membranoproliferative Glomerulonephritis | Drug: ACH-0144471 | Achillion Pharmaceuticals | Not recruiting | 16 Years | 65 Years | All | 6 | Phase 2 | Australia;Belgium;Netherlands | |
| 43 | ChiCTR-INR-17012212 | 2017-07-28 | 21 August 2017 | Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial | Use of sirolimus in patients with primary idiopathic membranous nephropathy: a prospective randomized control trial | idiopathic membranous nephropathy | 1:Cyclosporine;2:cyclosporine combined with sirolimus; | Renal Division, Peking University First Hospital | Recruiting | 18 | 70 | Both | 1:35;2:35; | New Treatment Measure Clinical Study | China | |
| 44 | ChiCTR-IPR-17011702 | 2017-07-01 | 6 November 2017 | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid | Compare of the treatment of membranous nephropathy with mizoribine and steroid or cyclophosphamide and steroid | membranous nephropathy | mizoribine group:treated with mizoribine and steroid;cyclophosphamide group:treated with cyclophosphamide and steroid; | Tianjin First Central Hospital | Not Recruiting | 18 | 65 | Both | mizoribine group:50;cyclophosphamide group:50; | Post-market | China | |
| 45 | NCT03180723 | July 1, 2017 | 16 December 2017 | Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis | Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis | Drug: Rituximab;Drug: Cyclosporin | Assiut University | Not recruiting | 18 Years | N/A | All | 30 | Phase 3 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT02921789 | May 22, 2017 | 26 August 2019 | Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients | A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients | Kidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS) | Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: Prednisone | Astellas Pharma Global Development, Inc. | Kyowa Kirin Co., Ltd. | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | United States;Canada |
| 47 | NCT02896270 | October 2016 | 16 December 2017 | Valproic Acid for Idiopathic Nephrotic Syndrome | A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome | Idiopathic Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Drug: Valproic Acid | Universitair Ziekenhuis Brussel | Recruiting | 18 Years | N/A | All | 15 | Phase 2/Phase 3 | Belgium | |
| 48 | NCT02683889 | August 2016 | 14 November 2016 | Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation | The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant | FSGS | Drug: Acthar | Georgetown University | Recruiting | 18 Years | 80 Years | Both | 20 | Phase 3 | United States | |
| 49 | NCT02966717 | August 2016 | 28 November 2016 | Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD) | The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease) | Renal Insufficiency, Chronic;Nephrotic Syndrome | Drug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cells | Zhujiang Hospital | Not recruiting | 18 Years | 65 Years | Both | 116 | Phase 2 | China | |
| 50 | NCT02633046 | May 16, 2016 | 30 September 2019 | Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria | Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE) | Idiopathic Focal Segmental Glomerulosclerosis | Drug: Acthar 80 U 3x/week;Other: Placebo;Drug: Acthar 80 U 2x/week | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 64 | Phase 4 | United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | JPRN-UMIN000022150 | 2016/04/30 | 2 April 2019 | The prospective single-center study on the efficacy and safety of rituximab for the treatment of adult and geriatric patients with primary nephrotic syndrome. | primary nephrotic syndrome | rituximab | Tokyo Metropolitan Geriatric Hospital | Recruiting | 18years-old | Not applicable | Male and Female | 50 | Not applicable | Japan | ||
| 52 | ChiCTR-IPR-16008344 | 2016-04-19 | 18 April 2017 | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid plus tacrolimus in idiopathic membranous nephropathy | A study for comparing alternating glucocorticoid and cyclophosphamide versus glucocorticoid Plus tacrolimus in idiopathic membranous nephropathy | idiopathic membranous nephropathy | A:cyclophosphamide ;B:tacrolimus; | Baoji Central Hospital | Recruiting | Both | A:30;B:30; | Post-market | China | |||
| 53 | NCT02592798 | March 1, 2016 | 26 August 2019 | Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) | A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease) | Nephrotic Syndrome;Focal Segmental Glomerulosclerosis;Minimal Change Disease | Other: D5W;Other: Normal Saline;Drug: Abatacept | Bristol-Myers Squibb | Not recruiting | 6 Years | N/A | All | 90 | Phase 2 | United States | |
| 54 | NCT02682407 | February 2016 | 22 January 2018 | Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease | IgAN;Lupus Nephritis;MN;C3G | Biological: OMS721;Other: Vehicle (D5W) | Omeros Corporation | Recruiting | 18 Years | N/A | All | 44 | Phase 2 | United States | |
| 55 | NCT02610595 | December 2015 | 7 December 2015 | Study on the Therapeutic Effect of TCM Treatment for MDR MN | A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation) | Idiopathic Membranous Nephropathy | Drug: Jianpixiaozhong particles and Wuse Dietotherapy | Shanghai University of Traditional Chinese Medicine | Fudan University;Ruijin Hospital;Shanghai 6th People's Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Changhai Hospital;Shanghai Putuo District Center Hospital;ShuGuang Hospital;Shanghai Yueyang Integrated Medicine Hospital;Shanghai Changzheng Hospital;Shanghai Minhang Central Hospital;Zhujiang Hospital;Guangxi Traditional Chinese Medical University;Huashan Hospital;The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine;Xinqiao Hospital of Chongqing;Guang'anmen Hospital of China Academy of Chinese Medical Sciences;Nanjing University of Traditional Chinese Medicine;Tongji Hospital;Chinese Academy of Sciences;RenJi Hospital | Not recruiting | 18 Years | 75 Years | Both | 220 | N/A | China |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT02585804 | September 2015 | 22 January 2018 | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects | Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study | Focal Segmental Glomerulosclerosis | Drug: Dapagliflozin | University Health Network, Toronto | AstraZeneca;University of Toronto;Toronto General Hospital | Not recruiting | 18 Years | N/A | All | 10 | Phase 4 | Canada |
| 57 | NCT02693366 | June 2015 | 16 December 2017 | Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis | Safety Study of the Endovascular Infusion of Bone Marrow Derived Mononuclear Cells in Patients With Focal Segmental Glomerulosclerosis | Glomerulosclerosis, Focal Segmental;Renal Insufficiency, Chronic | Biological: Autologous Cell Transplantation | Universidade Federal do Rio de Janeiro | Ministry of Science and Technology, Brazil;Ministry of Health, Brazil;National Research Council, Brazil;Rio de Janeiro State Research Supporting Foundation (FAPERJ) | Not recruiting | 18 Years | 60 Years | All | 5 | Phase 1 | Brazil |
| 58 | NCT02382874 | May 2015 | 14 December 2015 | Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) | Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical Trial | Focal Segmental Glomerulosclerosis | Biological: Intravenous injection | Royan Institute | Recruiting | 2 Years | 14 Years | Both | 5 | Phase 1 | Iran, Islamic Republic of | |
| 59 | EUCTR2014-002358-38-CZ | 28/04/2015 | 30 April 2019 | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL, DOSE-ESCALATION STUDY | FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) MedDRA version: 20.0 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Capsule INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: Aprovel (150 mg) Product Name: Aprovel 150 mg Tablets Pharmaceutical Form: Tablet INN or Proposed INN: Irbesartan CAS Number: 138402-11-6 Other descriptive name: IRBESARTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- Pharmaceutical form of the placebo: Capsule Route of administration of the placebo: Oral use Product Name: Sparsentan Product Code: RE-021 Pharmaceutical Form: Tablet INN or Proposed INN: Sparsentan CAS Number: 254740-64-2 Current Sponsor code: RE-021 Other descriptive name: SPARSENTAN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 400- | Retrophin, Inc. | Authorised | Female: yes Male: yes | 100 | Phase 2 | Czech Republic;Belgium;Italy | |||
| 60 | EUCTR2015-001039-18-Outside-EU/EEA | 4 August 2015 | Trial on the therapeutic effect of Tacrolimus in combination with low dosage corticosteroids compared with high dosage corticosteroids only, in patients with minimal change necrotic syndrome | Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf [Cap.]®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) - T_OPTIMUM study | Minimal change nephrotic syndrome;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Prograf Pharmaceutical Form: Capsule, hard INN or Proposed INN: TACROLIMUS CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5- Trade Name: Prograf Pharmaceutical Form: Capsule, hard INN or Proposed INN: TACROLIMUS CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Trade Name: Solondo Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Solondo Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- | Astellas Pharma Korea, Inc. | Not Available | Female: yes Male: yes | 152 | Korea, Republic of | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | ChiCTR-IPR-14005366 | 2014-09-01 | 18 April 2017 | A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapy | A prospective study of safety and efficacy in atypical membranous nephropathy by low-dose hormone combined immunosuppressive therapy | Atypical membranous nephropathy | Low-dose hormone plus cyclophosphamide (CTX) grou:hormone, cyclophosphamide, three months;hormone+CsA:hormone+CsA, three months; | Department of Nephrology, China-Japan Friendship Hospital | Recruiting | 18 | 70 | Both | Low-dose hormone plus cyclophosphamide (CTX) grou:20;hormone+CsA:20; | Post-market | ||
| 62 | ChiCTR-TRC-14005064 | 2014-09-01 | 18 April 2017 | A prospective study on the safety and efficacy of treatment with Qiluxiaobai formula for CKD 2-3 stage | Investigation on the Mechanisms Of Invigorating Spleen Dissipating Dampness Principle On The Treatment Of Podocyte Injury In Focal Segmental Glomerulosclerosis | chronic kidney disease | 1:basic treatment and losartan K 50mg qd;2:basic treatment and QLXB formula 200ml qd ; | Shanghai University of T.C.M | Recruiting | 18 | 60 | Both | 1:50;2:50; | Pilot study | China | |
| 63 | NCT02000440 | July 1, 2014 | 16 December 2017 | A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS) | Glomerulosclerosis, Focal Segmental | Drug: Losmapimod | GlaxoSmithKline | Not recruiting | 18 Years | 70 Years | All | 17 | Phase 2 | United States;Canada | |
| 64 | NCT02173106 | June 2014 | 19 February 2015 | A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy | Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial | Idiopathic Membranous Nephropathy;Proteinuria;Spontaneous Remission;Steroid Nephropathy;Cyclosporin Overdose | Drug: steroid & Cyclosporin | Sun Yat-sen University | Recruiting | 14 Years | 75 Years | Both | 180 | Phase 2 | China | |
| 65 | NCT02093533 | March 2014 | 29 January 2018 | Eculizumab in Primary MPGN | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Mario Negri Institute for Pharmacological Research | Alexion Pharma Italy s.r.l. | Not recruiting | N/A | 75 Years | All | 10 | Phase 2 | Italy |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | EUCTR2013-003826-10-IT | 24/01/2014 | 19 February 2018 | ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA - Eculizumab in primary MPGN | Membranoproliferative glomerulonephritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Soliris Product Name: Soliris Pharmaceutical Form: Concentrate for solution for injection/infusion INN or Proposed INN: ECULIZUMAB CAS Number: 219685-50-4 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 300- | IRCCS- Mario Negri Institute | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Italy | |||
| 67 | NCT01955187 | January 2014 | 14 January 2019 | Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy | European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study) | MEMBRANOUS NEPHROPATHY | Drug: TACROLIMUS;Drug: RITUXIMAB;Drug: METHYLPREDNISOLONE;Drug: CYCLOPHOSPHAMIDE | Hospital Universitario 12 de Octubre | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz;Hospital Universitario Fundación Alcorcón;Fundación para la Investigación Biomédica Hospital Universitario 12 de Octubre;Biobanco REDinREN;ERA-EDTA;REDinREN;Sociedad Española de Nefrología;Fundación de Investigación Biomédica - Hospital Universitario de La Princesa;University Hospital, Aachen | Not recruiting | 18 Years | N/A | All | 86 | Phase 3 | Spain |
| 68 | NCT01613118 | December 2013 | 11 June 2018 | Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis | Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study | Focal Segmental Glomerulosclerosis | Drug: RE-021 (Sparsentan);Drug: Irbesartan | Retrophin, Inc. | Not recruiting | 8 Years | 75 Years | All | 100 | Phase 2 | United States;Belgium;Czechia;Italy;Czech Republic | |
| 69 | NCT01573533 | October 2013 | 19 November 2018 | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS | A Pilot Study to Assess the Efficacy of Rituximab Therapy in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS): Integrating an Assessment of the Relevance of suPAR and Activation of Podocyte ß3 Integrin | Primary Focal Segmental Glomerulosclerosis | Biological: Rituximab | Mayo Clinic | University Health Network, Toronto;National Institutes of Health (NIH);Genentech, Inc.;Rush University Medical Center;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 6 Years | 80 Years | All | 20 | Phase 2 | United States;Canada |
| 70 | ChiCTR-TRC-13003783 | 2013-07-01 | 18 April 2017 | Compare the effects of intravenous to oral glucocorticoid therapies in MCNS patients with sever edema | Compare the effects of intravenous to oral glucocorticoid therapies in MCNS patients with sever edema | Minimal change nephroitic syndrome | treatment group:intravenous methylprednisolon;control:oral prednisone ; | the Affiliated Hospital of Guangdong Medical College | Not Recruiting | 14 | 60 | Both | treatment group:30;control:30; | Phase 4 study | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT01622738 | July 2013 | 19 February 2015 | A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis | A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis | Primary Focal Segmental Glomerulosclerosis | Drug: RE-021 | Retrophin, Inc. | Not recruiting | N/A | 50 Years | Both | 0 | N/A | United States | |
| 72 | NCT01762852 | April 2013 | 16 December 2017 | Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy | BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Belimumab 10 mg;Drug: Placebo | GlaxoSmithKline | Not recruiting | 18 Years | 75 Years | All | 0 | Phase 2 | United States;Australia;Canada;Czech Republic;France;Germany;Italy;Netherlands;Spain;United Kingdom | |
| 73 | EUCTR2011-000242-38-DE | 09/01/2013 | 4 November 2013 | A 2 year study to investigate belimumab in membranous nephropathy | BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy - GSK1550188 in membranous nephropathy | Idiopathic Membranous Nephropathy (IMN) MedDRA version: 16.0 Level: LLT Classification code 10027170 Term: Membranous nephropathy System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA® Product Name: BENLYSTA® Product Code: GSK1550188 (Belimumab) Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: BELIMUMAB CAS Number: 356547-88-1 Current Sponsor code: GSK1550881 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous use | GlaxoSmithKline Research & Development Ltd | Not Recruiting | Female: yes Male: yes | 94 | France;United States;Czech Republic;Canada;Spain;Australia;Netherlands;Germany;Italy;United Kingdom | ||||
| 74 | NCT01791686 | January 2013 | 19 February 2015 | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease | Dense Deposit Disease;Membranoproliferative Glomerulonephritis Type II;C3 Glomerulonephritis | Drug: CDX-1135 | Celldex Therapeutics | Not recruiting | 4 Years | N/A | Both | 1 | Phase 1 | United States | |
| 75 | JPRN-UMIN000008919 | 2012/09/15 | 2 April 2019 | The prospective multi-center study on the efficacy and safety of mizoribine for the treatment of aged nephrotic patients with primary membranous nephropathy. | The patients with nephrotic syndrome due to primary membranous nephropathy. | Treatment with a combination of mizoribine plus steroid therapy Treatment with steroid monotherapy | The study group of treatment for aged patients with nephrotic syndrome. | Not Recruiting | 65years-old | Not applicable | Male and Female | 200 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT01665391 | August 2012 | 19 February 2015 | A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) | A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis | Primary Focal Segmental Glomerulosclerosis | Drug: fresolimumab;Drug: Placebo | Genzyme, a Sanofi Company | Not recruiting | 18 Years | N/A | Both | 36 | Phase 2 | United States;Brazil;Germany;Italy;Spain | |
| 77 | NCT01763580 | July 16, 2012 | 20 May 2019 | A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome | Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS) | MCNS;Minimal Change Nephrotic Syndrome (MCNS) | Drug: Tacrolimus;Drug: Prednisolone | Astellas Pharma Korea, Inc. | Not recruiting | 16 Years | 78 Years | All | 144 | Phase 4 | Korea, Republic of | |
| 78 | EUCTR2011-006115-59-IT | 11/06/2012 | 31 July 2012 | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN) - GNM-2011 | MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens. The key role of IgG antibodies formation in the pathogenesis of IMN suggests that B cell depletion may favourably impact the evolution of the glomerular disease and reduce proteinuria. We propose this study in order to test in a randomized controlled trial the hyp MedDRA version: 14.1 Level: PT Classification code 10018372 Term: Glomerulonephritis membranous System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: MABTHERA*EV 1FL 50ML 500MG Pharmaceutical Form: Solution for injection CAS Number: 174722-31-7 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: URBASON*IM EV 1F 250MG+1F 5ML Pharmaceutical Form: Solution for infusion CAS Number: 83-43-2 Concentration unit: g gram(s) Concentration type: equal Concentration number: 1- Trade Name: MEDROL*10CPR DIV 4MG Pharmaceutical Form: Tablet CAS Number: 83-43-2 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: .4- Trade Name: ENDOXAN BAXTER*50CPR RIV 50MG Pharmaceutical Form: Coated tablet CAS Number: 50-18-0 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: equal Concentration number: .2- | AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA | Authorised | Female: yes Male: yes | Italy | |||||
| 79 | EUCTR2012-000385-38-GB | 18/05/2012 | 31 March 2014 | A study to investigate belimumab in IMGN | BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy | Idiopathic Membranous Glomerulonephropathy (IMGN) MedDRA version: 16.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: BENLYSTA® (belimumab) Product Name: Benlysta (belimumab) Product Code: GSK1550188 Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: Belimumab CAS Number: 356547-88-1 Current Sponsor code: GSK1550188 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 80- | GlaxoSmithKline Research and Development Ltd | Authorised | Female: yes Male: yes | 18 | United Kingdom | ||||
| 80 | NCT01164098 | February 2012 | 1 October 2018 | Rituximab to Prevent Recurrence of Proteinuria | The Use of Rituximab to Prevent Recurrence of Proteinuria in Patients Receiving Kidney Transplant for FSGS | FSGS;Proteinuria | Drug: Rituximab | George W. Burke | Genentech, Inc.;National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 7 Years | 65 Years | All | 30 | Phase 3 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 81 | NCT01508468 | January 2012 | 5 September 2016 | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy | Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Assistance Publique - Hôpitaux de Paris | Not recruiting | 18 Years | N/A | Both | 80 | Phase 3 | France | |
| 82 | NCT03018535 | January 2012 | 27 May 2019 | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Rituximab;Drug: Methylprednisolone;Drug: Cyclophosphamide | Azienda Ospedaliera Spedali Civili di Brescia | University of Bari;Azienda Ospedaliera Brotzu;University of Messina;University of Milan;Universita di Verona;University of Chieti;University of Bologna;Azienda Sanitaria Locale Roma E;Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi;Regione Piemonte;University of Modena and Reggio Emilia;University of Pisa;University of Milano Bicocca;Humanitas Hospital, Italy;Azienda Ospedaliera Universitaria Policlinico;Fondazione Salvatore Maugeri;University of Bern;University of Alberta;Istituto Giannina Gaslini | Not recruiting | 18 Years | N/A | All | 76 | Phase 3 | Italy |
| 83 | NCT01180036 | November 2011 | 21 January 2019 | MEmbranous Nephropathy Trial Of Rituximab | A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: Rituximab;Drug: Cyclosporine | Mayo Clinic | Columbia University;University of British Columbia;Ohio State University;Stanford University;University of Washington;University of Michigan;University of Alabama at Birmingham;Case Western Reserve University;The Cleveland Clinic;University of Kansas Medical Center;University of Manchester;University Health Network, Toronto;University of Toronto;CHU de Quebec-Universite Laval;Washington University School of Medicine;Florida International University;University of Mississippi Medical Center;New York University School of Medicine;Medical College of Wisconsin;University of Arizona;Sunnybrook Health Sciences Centre;Applied Health Research Centre;Fulk Family Foundation | Not recruiting | 18 Years | 80 Years | All | 126 | Phase 2/Phase 3 | United States;Canada |
| 84 | NCT01845688 | November 2011 | 14 December 2015 | Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy | Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study | Idiopathic Membranous Nephropathy | Drug: Losartan Tablets & QingReMoShen Granule;Drug: Losartan Tablets & Placebo Granule | wanglin | Not recruiting | 18 Years | 70 Years | Both | 72 | N/A | China | |
| 85 | NCT01451489 | October 13, 2011 | 16 December 2017 | The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis | A Randomized,Multicentre,Prospective Study on the Tacrolimus(FK506)for Focal Segmental Glomerulosclerosis | FSGS | Drug: FK506;Drug: Cyclophosphamide | Nanjing University School of Medicine | Not recruiting | 14 Years | 65 Years | All | 70 | N/A | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 86 | ChiCTR-TRC-11001454 | 2011-08-01 | 18 April 2017 | Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial | Tacrolimus monotherapy follows intravenous methylprednisolone in adults with minimal change nephrotic syndrome: a prospective, multi-centered, open, randomized, controlled trial | minimal change disease in adults;ICD10:N04.001 | Group A:Tacrolimus orally taken 0.5-1mg q12h for 36w, tape;Group B:prednisone orally taken for 36w, 1.0 mg/kg.d, tape; | Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University | Not Recruiting | Both | Group A:60;Group B:60; | Post-market | China | |||
| 87 | NCT01386554 | August 2011 | 11 June 2018 | Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients | A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN) | Proteinuria;Idiopathic Membranous Nephropathy | Drug: Repository Corticotropin Injection;Drug: Placebo | Mallinckrodt | Not recruiting | 18 Years | N/A | All | 60 | Phase 4 | United States;Canada;Chile;Mexico;Turkey | |
| 88 | JPRN-UMIN000005231 | 2011/03/01 | 2 April 2019 | Uncontrol trial of rituximab treatment on steroid dependent and frequently relapsing minimal cahnge nephrotic syndrome(MCNS) | steroid dependent and frequently relapsing minimal change nephrotic syndrome | rituximab 375mg/m2 single-dose 1 time/6months 24 months follow up | Department of Medicine, Kidney Center, Tokyo Women's Medical University | Not Recruiting | 20years-old | 60years-old | Male and Female | 50 | Phase 3 | Japan | ||
| 89 | NCT01282073 | March 2011 | 20 April 2015 | Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy | A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy | Glomerulonephritis, Membranous | Drug: Mycophenolate mofetil, low dose steroid;Drug: Cyclosporin, low dose steroid | Kyungpook National University | Hanmi Pharmaceutical Company Limited | Recruiting | 18 Years | N/A | Both | 62 | Phase 3 | Korea, Republic of |
| 90 | NCT00977977 | December 23, 2010 | 7 October 2019 | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy | Nephrotic Syndrome;Proteinuria;Autoimmune Disease;Glomerular Disease;Membranous Glomerulonephritis | Drug: Rituximab Infusion;Drug: Oral Cyclosporine | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 91 | NCT01799460 | December 2010 | 19 February 2015 | Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy | Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies | Idiopathic Membranous Nephropathy | Drug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine;Drug: The immunosuppressive agents | Shanghai University of Traditional Chinese Medicine | Recruiting | 18 Years | 70 Years | Both | 80 | N/A | China | |
| 92 | NCT01093781 | November 2010 | 19 February 2015 | Aliskiren in Patients With Idiopathic Membranous Nephropathy | A Pilot Study to Evaluate the Antiproteinuric Effect of Renin Inhibition With Aliskiren in Patients With Idiopathic Membranous Nephropathy | Idiopathic Membranous Nephropathy | Drug: Aliskiren | Mayo Clinic | Not recruiting | 18 Years | 80 Years | Both | 0 | N/A | United States | |
| 93 | ChiCTR-TRC-10000871 | 2010-09-01 | 18 April 2017 | A randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndrome | A randomized post-market trial of Huang Qi Huai for chilhood steroid-sensitive nephrotic syndrome | Steroid-sensitive primary nephrotic syndrome in children | Group A:Prednisolone (tablets) + Huai Qi Huang (particle);Group B:Prednisolone (tablets) + placebo (particle); | Children's Hospital Affiliated to Fudan UniversityNanjing Children's Hospital | Not Recruiting | 1 | 12 | Both | Group A:50;Group B:50; | Post-market | China | |
| 94 | NCT01185197 | September 2010 | 11 June 2018 | Myfortic® for Minimal Change Nephrotic Syndrome (MCNS): a Randomized Study | Myfortic® Combined With Low-dose Steroid in Minimal Change Nephrotic Syndrome | Nephrosis, Lipoid | Drug: Myfortic plus low-dose steroid;Drug: Prednisolone | The University of Hong Kong | Not recruiting | 18 Years | 65 Years | All | 20 | Phase 4 | China | |
| 95 | NCT01162005 | July 2010 | 7 November 2016 | Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children | Therapeutic Effect of Tacrolimus on Primary Nephrotic Syndrome in Children | Nephrotic Syndrome | Drug: Tacrolimus | Seoul National University Hospital | Chong Kun Dang Pharmaceutical | Not recruiting | N/A | 18 Years | Both | 80 | Phase 4 | Korea, Republic of |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 96 | NCT01221181 | July 2010 | 4 March 2019 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | Dense Deposit Disease;Membranoproliferative Glomerulonephritis | Drug: Eculizumab | Columbia University | Alexion Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 6 | Phase 1 | United States |
| 97 | NCT01161459 | June 2010 | 19 February 2015 | Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid | Research Institute of Nephrology, Jinling Hospital | Idiopathic Membranous Nephropathy | Drug: Tripterygium wilfordii;Drug: FK506 | Zhi-Hong Liu, M.D. | Not recruiting | 18 Years | 65 Years | Both | 100 | N/A | China | |
| 98 | EUCTR2009-016003-26-GB | 06/05/2010 | 20 March 2012 | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | RANDOMISED PILOT TRIAL OF MYFORTIC FOR THE TREATMENT OF PRIMARY PROTEINURIC GLOMERULONEPHRITIS. - GloMY - Proteinuria in glomerulonephritis : Myfortic | Primary Proteinuric Glomeruolnephritis Focal segmental glomeruloscerosis and IgA nephropathy MedDRA version: 14.1 Level: PT Classification code 10067757 Term: Focal segmental glomerulosclerosis System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: PT Classification code 10021263 Term: IgA nephropathy System Organ Class: 10038359 - Renal and urinary disorders | Trade Name: Myfortic Product Name: Myfortic 360mg Tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mycophenolic acid CAS Number: 24280-93-1 Other descriptive name: mycophenolate sodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 360- Trade Name: Myfortic Product Name: Myfortic 180mg Tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: mycophenolic sodium CAS Number: 24280-93-1 Other descriptive name: mycophenolate sodium Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 180- Product Name: Prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: prednisolone CAS Number: 50-24-8 Concentration unit: mg milligram(s) Concentration type: range Concentration number: 1.0-25.0 | UHB NHS Foundation Trust | Authorised | Female: yes Male: yes | 100 | United Kingdom | ||||
| 99 | NCT01093157 | February 2010 | 16 December 2017 | A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy | A Dose-finding Pilot Study of ACTH (Adrenocorticotropic Hormone) on the Proteinuria and Serum Lipoprotein Profile in Patients With Idiopathic Membranous Nephropathy (MN) | Glomerulonephritis | Drug: Adrenocorticotrophic hormone ACTH | University Health Network, Toronto | Mallinckrodt | Not recruiting | 18 Years | 72 Years | All | 10 | Phase 1/Phase 2 | Canada |
| 100 | ChiCTR-TQR-12002602 | 2009-10-09 | 18 April 2017 | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | The Effects of an Combinedative Treatment of with Prednisone plus and Fluvastatin on the Levels of Cholesterol and Bilirubin in the Patients with Minimal Change Nephropathy | Minimal change nephrotic syndrome in children | Treatment:prednisone 1~2 mg/kg/day+Fluvastatin Sodium Capsule;Control:prednisone 1~2 mg/kg/day; | Treatment center of kidney disease, 281th hospital of PLA | Not Recruiting | 4 | 12 | Both | Treatment:30;Control:30; | Phase 1 study | China | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 101 | NCT01113385 | October 2009 | 19 October 2017 | Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome | Effect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot Study | Focal Segmental Glomerulosclerosis;Steroid Resistant Nephrotic Syndrome | Drug: D-Galactose | Children's Research Institute | National Kidney Foundation | Not recruiting | 2 Years | 21 Years | All | 7 | N/A | United States |
| 102 | NCT01197040 | October 2009 | 16 December 2017 | Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome | Low Steroid Dose Combined With Mycophenolic Acid (Myfortic) Compared With High Dose Steroid for Minimal Change Nephrotic Syndrome | Nephrotic Syndrome | Drug: Prednisone;Drug: acid mycophenolic (Myfortic) | Assistance Publique - Hôpitaux de Paris | Novartis | Not recruiting | 18 Years | N/A | All | 117 | Phase 3 | France |
| 103 | NCT00956059 | September 2009 | 19 February 2015 | Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis | Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: prednisone, FK506, MMF;Drug: prednisone | Xi’an Jiaotong University College of Medicine | Not recruiting | 16 Years | 70 Years | Both | 40 | N/A | China | |
| 104 | NCT01129557 | September 2009 | 19 October 2017 | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease | Aldosterone Breakthrough During Diovan (Valsartan), Tekturna (Aliskiren), and Combination (Valsartan+Aliskiren) Anti-hypertensive Therapy in Patients With Proteinuric Kidney Disease | Proteinuric Kidney Disease;Diabetic Nephropathy;Hypertensive Nephrosclerosis;IgA Nephropathy;Focal Segmental Glomerulosclerosis;Glomerulopathy (Obesity-associated);Glomerulonephritis, Membranous | Drug: Aliskiren;Drug: Valsartan | Columbia University | Novartis Pharmaceuticals | Not recruiting | 18 Years | N/A | All | 46 | Phase 4 | United States |
| 105 | NCT01155141 | September 2009 | 19 October 2017 | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH | Kidney Diseases | Drug: H.P. Acthar Gel | Stanford University | Mallinckrodt | Not recruiting | 16 Years | 65 Years | All | 15 | Phase 4 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 106 | EUCTR2008-006750-17-IT | 14/04/2009 | 28 August 2012 | A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMO | A prospective, sequential study to assess the efficacy of rituximab therapy in maintaining remission of nephrotic syndrome after steroid and immunosuppressive therapy withdrawal in patients with steroid-dependant or multirelapsing minimal change disease or focal segmental glomerulosclerosis - NEMO | Nephrotic Syndrome secondary to minimal change disease (MCD) or idiopathic focal and segmental glomerulosclerosis (FSGS. MedDRA version: 9.1 Level: LLT Classification code 10029171 MedDRA version: 9.1 Level: LLT Classification code 10058326 MedDRA version: 9.1 Level: LLT Classification code 10016832 | Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100- Trade Name: MABTHERA Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Rituximab Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500- | IST. DI RICERCHE FARMACOLOG. M. NEGRI | Not Recruiting | Female: yes Male: yes | Italy | |||||
| 107 | ChiCTR-ONC-12002809 | 2009-01-01 | 18 April 2017 | Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome | Clinical Study of Prediction of Glucocorticoid Efficacy by cytokins in Patients with Primary Nephrotic Syndrome | Idiopathic nephrotic syndrome | 1:Given methylprednisolone according to the status of the patients ; | The First Affiliated Hospital of Dalian Medical University | Not Recruiting | 18 | 75 | Both | 1:90; | Other | China | |
| 108 | NCT00801463 | January 2009 | 19 February 2015 | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Proteinuria;Focal Segmental Glomerulosclerosis | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | Not recruiting | 18 Years | 60 Years | Both | 67 | N/A | China | |
| 109 | NCT00805753 | January 2009 | 19 February 2015 | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy | A Dose-Finding Pilot Study of ACTH on the Serum Lipoprotein Profile and Proteinuria in Patients With Idiopathic Membranous Nephropathy (MN) | Idiopathic Membranous Nephropathy | Drug: ACTH | Mayo Clinic | Questcor Pharmaceuticals, Inc. | Not recruiting | 18 Years | N/A | Both | 20 | Phase 1 | United States;Canada |
| 110 | NCT00814255 | December 2008 | 19 October 2017 | Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial | Novel Therapies for Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactose | New York University School of Medicine | University of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 1 Year | 65 Years | All | 32 | Phase 2 | United States;Canada |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 111 | NCT00816478 | December 2008 | 21 September 2015 | Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | Not recruiting | 2 Years | 60 Years | Both | 15 | Phase 1 | United States | |
| 112 | NCT00816504 | December 2008 | 14 September 2015 | Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5 | Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5 | Focal Segmental Glomerulosclerosis | Drug: Galactose | North Shore Long Island Jewish Health System | Medical College of Wisconsin | Not recruiting | 2 Years | 60 Years | Both | 0 | Phase 1 | United States |
| 113 | NCT00694863 | July 2008 | 19 February 2015 | Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy | Treatment With Synthetic Adrenocorticotropic Hormone (ACTH) in Patients With Membranous Nephropathy and High Risk for Renal Failure. A Pilot Study | Idiopathic Membranous Nephropathy | Drug: tetracosactide hexacetaat | Radboud University | Dutch Kidney Foundation | Not recruiting | 18 Years | 95 Years | Both | 20 | Phase 2 | Netherlands |
| 114 | EUCTR2007-005410-39-ES | 11/06/2008 | 19 March 2012 | “Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC | “Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática” - MEMTAC | La nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complejos inmunes a lo largo del espacio subepitelial, en ausencia de inflamación o cambios proliferativos en el resto del glomérulo. El origen exacto de este trastorno se desconoce sin embargo se sabe que la NMI es una causa frecuente de síndrome nefrótico (SN) del adulto. MedDRA version: 9.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy | Trade Name: Advagraf 0,5mg Pharmaceutical Form: Capsule* INN or Proposed INN: tacrolimus CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0,5- Trade Name: Genoxal Pharmaceutical Form: Tablet INN or Proposed INN: ciclofosfamida CAS Number: 50-18-0 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Trade Name: Dacortín 2,5mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisona CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2,5- Trade Name: Advagraf 1mg Pharmaceutical Form: Capsule* INN or Proposed INN: tacrolimus CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Trade Name: Advagraf 5mg Pharmaceutical Form: Capsule* INN or Proposed INN: tacrolimus CAS Number: 104987-11-3 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Dacortín 5mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisona CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 5- Trade Name: Dacortín 30mg Pharmaceutical Form: Tablet INN or Proposed INN: prednisona CAS Number: 53-03-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 30- | Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología. | Authorised | Female: yes Male: yes | 40 | Spain | ||||
| 115 | EUCTR2008-001647-19-NL | 22/05/2008 | 19 March 2012 | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Membranous nephropathy MedDRA version: 9.1 Level: LLT Classification code 10027170 Term: Membranous nephropathy | Trade Name: Synacthen Depot 1mg Pharmaceutical Form: Suspension for injection | Radboud University Nijmegen Medical Center | Authorised | Female: yes Male: yes | Netherlands | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 116 | ChiCTR-TRC-08000098 | 2008-04-01 | 18 April 2017 | Reseaech on integrated therapy of traditional Chinese medicine for membranous nephropathy | Reseaech on integrated therapy of traditional Chinese medicine for membranous nephropathy | Idiopathic membranous nephropathy | Treatment group:Integrated therapy of TCM;Control group:Prednisone and CTX; | Longhua Hospital Affiliated to Shanghai University of TCM | Not Recruiting | 18 | 75 | Both | Treatment group:95;Control group:95; | Phase 1 study | China | |
| 117 | NCT00782561 | April 2008 | 26 August 2019 | Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS) | A Phase I, Open-Label Study of the Safety and Pharmacokinetics of FG-3019 in Adolescent and Adult Subjects With Steroid-Resistant Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Drug: FG-3019 | FibroGen | Not recruiting | 12 Years | 64 Years | All | 2 | Phase 1 | United States | |
| 118 | ChiCTR-TRC-10001024 | 2008-01-01 | 18 April 2017 | Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis | Tacrolimus versus Cyclophosphamide for Therapy in steroid-resistant and steroid-dependent primary focal segmental glomerulosclerosis | primary focal segmental glomerulosclerosis | group A:intravenous CTX 0.5-0.75g/m2 Monthly+Oral prednisone (Prednisolone) 0.8mg/kg.d ;group B:Oral FK506 FK506 0.1mg/kg.d+prednisone (Prednisolone) 0.5mg/kg.d ; | Shanghai Jiaotong University Affiliated Ruijin Hospital | Not Recruiting | 18 | 75 | Both | group A:30;group B:30; | Post-market | China | |
| 119 | NCT00550342 | January 2008 | 16 December 2017 | Rituximab Treatment of Focal Segmental Glomerulosclerosis | Anti-CD20, Rituximab, for the Treatment of Recurrent or Primary Resistant Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis (FSGS) | Drug: rituximab | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Genentech, Inc.;Indiana University | Not recruiting | 5 Years | 60 Years | All | 10 | Phase 2 | United States |
| 120 | JPRN-UMIN000000963 | 2007/10/01 | 2 April 2019 | Efficacy and safety of cyclosporine and steroid for the treatment of minimal change nephrotic syndrome | Minimal change nephrotic syndrome | administration of cyclosporine | Yoshihiko Saito | Not Recruiting | 20years-old | 75years-old | Male and Female | 30 | Not applicable | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 121 | JPRN-UMIN000001099 | 2007/10/01 | 2 April 2019 | Optimal use of ciclosporin in idiopathic membranous nephropathy associated with nephrotic syndrome | idiopathic membranous nephropathy associated with nephrotic syndrome | Steroid group: Immunosuppressive therapy is started by predonisolone 0.8mg/kg/day (max 60mg/day). The dose is decreased by 5mg/day in 2 to 4 weeks after remission. The cases who do not reach remission for 4 weeks, predonisolone is decreased to 0.6mg/kg/day, and ciclosporin (2mg/kg/day) is started once a day. Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) Steroid + ciclosporin group: Immunosupressive therapy is started by predonisolone 0.6mg/kg/day and ciclosporin 2mg/kg/day (once a day). Serum concentration of ciclosporin is measured 2hr after administration, and the dose is adjusted. (The target serum concentration is 800-1000ng/mL.) The dose of predonisolone is decreased by 5mg/day in 2 to 4 weeks after remission. Ciclosporin is continued after remission. (The target C2 is 600-800 ng/mL.) The cases who do not reach remission after 4 weeks, predonisolone is decreased by 5mg/4-8week, and ciclosporin is continued for 6 months. The target C2 is 800-1000ng/mL. At 6 months after, the therapy of non-respnder is not restricted. | Division of Kidney and Dialysis, Department of Internal Medicine,Hyogo College of Medicine | 16years-old | Not applicable | Male and Female | 50 | Phase 4 | Japan | |||
| 122 | NCT00479622 | August 2007 | 19 February 2015 | Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus | A Randomized, Two-Arm, Parallel Group Study of the Safety, Pharmacokinetics, and Pharmacodynamics of TRU-015 Added to Standard Therapy in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: TRU-015 | Wyeth is now a wholly owned subsidiary of Pfizer | Emergent Product Development Seattle LLC | Not recruiting | 18 Years | 70 Years | Both | 20 | Phase 1 | United States |
| 123 | NCT00464321 | May 2007 | 19 February 2015 | Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS | A Phase I, Multicentre, Open-label, Dose-escalating Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic Focal Segmental Glomerulosclerosis (FSGS) | Focal Segmental Glomerulosclerosis | Biological: GC1008 | Genzyme, a Sanofi Company | Not recruiting | 18 Years | N/A | Both | 16 | Phase 1 | United States;Germany;Italy;United Kingdom | |
| 124 | JPRN-UMIN000000621 | 2007/03/01 | 2 April 2019 | Okayama nephrotic syndrome treatment group: Study group for short-term combination therapy of angiotensin-2 receptor blocker and cyclosporine for keeping remission | Minimal change nephrotic syndrome | Prednisolone (+), combination therapy (-) Prednisolone (+), combination therapy (+) | Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan | Not Recruiting | 16years-old | Not applicable | Male and Female | 50 | Not selected | Japan | ||
| 125 | NCT00405340 | October 2006 | 2 November 2015 | Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Membranous Nephropathy | Drug: Rituximab | Mayo Clinic | Genentech, Inc. | Not recruiting | 18 Years | N/A | Both | 20 | Phase 0 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 126 | NCT00354731 | August 2006 | 19 February 2015 | Efficacy of Pentoxifylline on Primary Nephrotic Syndrome | Clinical Efficacy of Pentoxifylline on Patients With Primary Nephrotic Syndrome | Nephrotic Syndrome | Drug: pentoxifylline;Drug: Corticosteroid | National Taiwan University Hospital | National Science Council, Taiwan | Not recruiting | 20 Years | 80 Years | Both | 62 | Phase 3 | Taiwan |
| 127 | ChiCTR-OPN-17012789 | 2006-06-01 | 2 October 2017 | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | focal segmental glomerulosclerosis | study group:prednisone treatment;control group:ACEI/ARB; | Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | Not Recruiting | 17 | 80 | Both | study group:52;control group:50; | Post-market | China | |
| 128 | EUCTR2005-004460-22-BE | 12/05/2006 | 7 October 2014 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to corticosteroids with ACE-inhibitors in the treatment of de novo nephrotic syndrome due to focal segmental glomerulosclerosis. | focal and segmental glomerulosclerosis | Trade Name: Neoral Product Name: Neoral Pharmaceutical Form: Capsule* Trade Name: Medrol Product Name: Medrol Pharmaceutical Form: Tablet Trade Name: zestril Product Name: zestril Pharmaceutical Form: Tablet | Hopital Erasme | Authorised | Female: yes Male: yes | 50 | Belgium | ||||
| 129 | EUCTR2005-004469-40-BE | 12/05/2006 | 7 October 2014 | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndrome due to idiopathic membranous glomerulopathy | Membranous Nephropathy | Trade Name: Neoral Product Name: Neoral Pharmaceutical Form: Capsule* Trade Name: zestril Product Name: zestril Pharmaceutical Form: Tablet | Hopital Erasme | Authorised | Female: yes Male: yes | 50 | Belgium | ||||
| 130 | JPRN-C000000158 | 2006/03/01 | 2 April 2019 | Mizoribin for primary nephrotic syndrome in children(JSRDC09) | Steroid-sensitive nephrotic syndrome | mizoribine+prednisolone | Japanese Study Group of Renal Disease in Children(JSRDC) | Not Recruiting | 1years-old | 10years-old | Male and Female | 50 | Not selected | Japan | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 131 | NCT00302523 | March 2006 | 19 February 2015 | Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy | Tacrolimus Treatment of Patients With Idiopathic | Idiopathic Membranous Nephropathy | Drug: Tacrolimus | Nanjing University School of Medicine | Not recruiting | 18 Years | 60 Years | Both | 16 | N/A | China | |
| 132 | NCT00302536 | March 2006 | 19 February 2015 | Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis | Tacrolimus Treatment of Patients With Idiopathic Focal Segmental | Focal Glomerulosclerosis | Drug: Tacrolimus | Nanjing University School of Medicine | Not recruiting | 15 Years | 50 Years | Both | 0 | N/A | China | |
| 133 | NCT00983034 | March 2006 | 19 February 2015 | The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy | Prospective Study of the Effects of Helicobacter Pylori Eradication on Renal Functions and Proteinuria in Patients With Membranous Nephropathy | Nephrotic Syndrome;Glomerulonephritis;Membranous Nephropathy | Drug: lansoprazole, amoxicillin, clarithromycin | Istanbul University | Not recruiting | 18 Years | 70 Years | Both | 70 | N/A | Turkey | |
| 134 | NCT00275613 | November 2005 | 19 February 2015 | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis | Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis | Glomerulonephritis, Membranoproliferative | Drug: Rituximab | Mayo Clinic | Not recruiting | 18 Years | N/A | Both | 10 | Phase 1 | United States | |
| 135 | NCT00193648 | July 2005 | 19 February 2015 | Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS) | Novel Therapies for Resistant FSGS | Focal Glomerulosclerosis | Drug: Rosiglitazone (Avandia);Drug: Adalimumab (Humira) | North Shore Long Island Jewish Health System | University of North Carolina;The Cleveland Clinic | Not recruiting | 2 Years | 40 Years | Both | 21 | Phase 1 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 136 | JPRN-UMIN000004653 | 2005/01/01 | 2 April 2019 | The clinical effects and safty of cyclosporine with rootine corticosteroid treatment in onset MCNS | minimal change nephrotic syndrome | cyclosporine A 2-3mg/kg/day | Yokohama city university graduate school of medicine | Not Recruiting | 16years-old | Not applicable | Male and Female | 20 | Not applicable | Japan | ||
| 137 | NCT00135811 | November 2004 | 19 February 2015 | Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT) | Focal Segmental Glomerulosclerosis Clinical Trial | Glomerulosclerosis, Focal | Drug: Cyclosporin;Drug: MMF and Dexamethasone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | The Cleveland Clinic | Not recruiting | 2 Years | 40 Years | Both | 207 | Phase 3 | United States |
| 138 | NCT00362531 | November 2004 | 19 February 2015 | Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Idiopathic Membranous Nephropathy;Nephrotic Syndrome | Drug: tacrolimus combined with prednisone | Peking University | Not recruiting | 18 Years | 70 Years | Both | Phase 2/Phase 3 | |||
| 139 | NCT00425217 | August 2004 | 19 February 2015 | Rituximab in Membranous Nephropathy | The Use of Rituximab in the Treatment of Idiopathic Membranous Nephropathy | Membranous Nephropathy | Drug: Rituximab | Mayo Clinic | Genentech, Inc. | Not recruiting | 18 Years | N/A | Both | 15 | Phase 2/Phase 3 | United States |
| 140 | ChiCTR1900022518 | 2004-04-01 | 23 April 2019 | Clinical trial for corticosteroids monotherapy in the treatment of seronegative hepatitis B virus-associated membranous nephropathy. | Efficacy and safety of corticosteroids in 26 cases of seronegative hepatitis B virus-associated membranous nephropathy | Seronegative Hepatitis B Virus-associated Membranous Nephropathy | Case series:give corticosteroids(Methylprednisolone); | Tianjin Hospital | Not Recruiting | Both | Case series:26; | Phase 0 | China | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 141 | JPRN-C000000368 | 2004/04/01 | 2 April 2019 | Multicenter study for combined therapy of prednisolone and mizoribine in idiopathic membranous nephropathy with refractory nephrotic syndrome | membranous nephropathy with primary steroid resistant nephrotic syndrome | mizoribine once a day per os administration (150mg) after breakfast for 2years. mizoribine 3 times a day per os administration (50mg each) after meals for 2years. | Project team for treatment of refractory nephrotic syndrome | The Progressive Renal Disease Research Projects in the Ministry of Health, Labor and Welfare, Japan | Not Recruiting | 16years-old | 75years-old | Male and Female | 100 | Not selected | Japan | |
| 142 | ChiCTR-TRC-09000539 | 2004-03-01 | 18 April 2017 | Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy | Clinical studies of tacrolimus in idiopathic membranous Nephropathy with nephrotic syndrome therapy | Nephrotic Disease | S:Patients receive tacrolimus combined with prednison for six months;L:Patients receive tacrolimus combined with prednison for 24 months; | Second Hospital of Jilin University | Not Recruiting | 16 | 69 | Both | S:10;L:10; | Pilot study | China | |
| 143 | NCT00404833 | January 2003 | 19 February 2015 | Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental | A Prospective Randomized Open-label Study to Compare Mycophenolate Mofetil and Corticosteroid With Conventional Immunosuppressive Treatment on Proteinuria in Idiopathic Membranous Nephropathy (MN) and Focal Segmental Glomerulosclerosis (FSGS) | Glomerulonephritis, Membranous;Glomerulosclerosis, Focal | Drug: prednisolone and mycophenolate mofetil;Drug: prednisolone and chlorambucil | Hospital Authority, Hong Kong | The University of Hong Kong | Not recruiting | 18 Years | 65 Years | Both | 16 | Phase 3 | China |
| 144 | NCT00050713 | December 17, 2002 | 16 December 2017 | Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy | Sirolimus Therapy in Idiopathic and Lupus Membranous Nephropathy | Membranous Glomerulonephritis;Lupus Membranous Nepropathy | Drug: Sirolimus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 13 Years | N/A | All | 12 | Phase 2 | United States | |
| 145 | NCT00040508 | June 2002 | 19 February 2015 | Sirolimus for Focal Segmental Glomerulosclerosis | Sirolimus for Focal Segmental Glomerulosclerosis | Focal Glomerulosclerosis | Drug: Sirolimus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | N/A | N/A | Both | 30 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 146 | NCT00135967 | May 2002 | 19 February 2015 | Mycophenolate Mofetil in Membranous Nephropathy | Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study | Glomerulonephritis, Membranous | Drug: mycophenolate mofetil orally 1000 mg twice a day (BID);Drug: prednisone 0,5 mg/kg orally on alternate days;Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9 | Radboud University | Hoffmann-La Roche | Not recruiting | 18 Years | 75 Years | Both | 30 | Phase 2/Phase 3 | Netherlands |
| 147 | JPRN-C000000009 | 2001/04/01 | 2 April 2019 | Treatment for steroid-resistant nephrotic syndrome in children: a combination of cyclosporine and prednisolone in minimal change and a combination of methylprednisolone, cyclosporine and prednisolone in FSGS | Steroid-resistant nephrotic syndrome in children | Cyclosporine+prednisolone Methylprednisolone+cyclosporine+prednisolone | Japanese Study Group of Renal Disease in Children | Not Recruiting | 1years-old | 18years-old | Male and Female | 60 | Not selected | Japan | ||
| 148 | JPRN-C000000379 | 2001/04/01 | 2 April 2019 | Prednisolone only and a combination of prednisolone and mizoribine for primary nephrotic syndrome relapsed within six mounths after first onset in children: A randomized controlled trial of efficacy and safety (JSRDC06) | Steroid-sensitive nephrotic syndrome | prednisolone mizoribine+prednisolone | Japanese Study Group of Renal Disease in Children(JSRDC) | Not Recruiting | 1years-old | 10years-old | Male and Female | 50 | Not selected | Japan | ||
| 149 | NCT00007475 | December 2000 | 19 October 2017 | Permeability Factor in Focal Segmental Glomerulosclerosis | Permeability Factor in Focal Segmental Glomerulosclerosis | Focal Segmental Glomerulosclerosis | Procedure: Plasma exchange;Drug: Cyclophosphamide | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | N/A | N/A | All | 15 | Phase 1/Phase 2 | United States | |
| 150 | NCT00004990 | March 2000 | 19 February 2015 | Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis | Pulse Dexamethasone in Focal Segmental Glomerulosclerosis | Glomerulonephritis;Nephrotic Syndrome | Drug: Dexamethasone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | N/A | N/A | Both | 20 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 151 | NCT00001959 | December 1999 | 19 October 2017 | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) | Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study | Fibrosis;Focal Glomerulosclerosis;Kidney Failure;Nephrotic Syndrome;Proteinuria | Drug: Pirfenidone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not recruiting | 18 Years | N/A | All | 21 | Phase 2 | United States | |
| 152 | NCT00135954 | July 1997 | 19 February 2015 | Treatment of Patients With Idiopathic Membranous Nephropathy | Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy | Glomerulonephritis, Membranous | Drug: Cyclophosphamide and steroids | Radboud University | Not recruiting | 18 Years | 75 Years | Both | 29 | Phase 3 | Netherlands |